A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting

E. Antonio Chiocca, Khalid M. Abbed, Stephen Tatter, David N. Louis, Fred H. Hochberg, Fred Barker, Jean Kracher, Stuart A. Grossman, Joy D. Fisher, Kathryn Carson, Mark Rosenblum, Tom Mikkelsen, Jeff Olson, James Markert, Steven Rosenfeld, L. Burt Nabors, Steven Brem, Surasak Phuphanich, Scott Freeman, Rick KaplanJames Zwiebel

Research output: Contribution to journal › Article › peer-review

287 Scopus citations

Fingerprint

Dive into the research topics of 'A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds